U.S. Appeals Court Rules to Reopen Lawsuit Over Tylenol and Autism/ADHD
The U.S. Appeals Court ruled on 7 month 13 day to allow the reopening of a personal lawsuit claiming a connection between the use of Tylenol (acetaminophen) and autism/Attention Deficit Hyperactivity Disorder (ADHD), leading to a resumption of legal proceedings against the manufacturer. However, it has also been reported that there is currently no definitive scientific evidence linking Tylenol use during pregnancy to these conditions.
The U.S. Appeals Court ruled on 7 month 13 day to allow the reopening of a personal lawsuit claiming a connection between the use of Tylenol (acetaminophen) and autism/Attention Deficit Hyperactivity Disorder (ADHD), leading to a resumption of legal proceedings against the manufacturer. Investors now need to check the company's litigation exposure and relevant disclosures.
Plaintiffs claimed that using Tylenol during pregnancy is related to the onset of autism or ADHD in their children and sought damages. This ruling opens the path for such claims to be reconsidered in court.
According to reports, there is currently no definitive scientific evidence that links the use of Tylenol during pregnancy with autism or ADHD. Scientific evidence and legal judgments are being handled separately.
The ruling is a decision aimed at private lawsuits. Specific trial schedules and the possibility of further appeals need to be confirmed through future court documents and disclosures.
The timing of this decision is 2026 year 7 month 13 day. Investor interest may be concentrated depending on the outcome of the case and the company's disclosure details.
Sources: CNBC Top News,Investing.com News
Bullstory synthesized this report from the linked sources. AI may have assisted the writing process. Check the original reports for factual confirmation.